A citation-based method for searching scientific literature

Richard A Ward, Stephen Fawell, Nicolas Floc'h, Vikki Flemington, Darren McKerrecher, Paul D Smith. Chem Rev 2021
Times Cited: 56







List of co-cited articles
160 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A view on drug resistance in cancer.
Neil Vasan, José Baselga, David M Hyman. Nature 2019
536
21

Cancer drug resistance: an evolving paradigm.
Caitriona Holohan, Sandra Van Schaeybroeck, Daniel B Longley, Patrick G Johnston. Nat Rev Cancer 2013
10

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
10

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
8

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
8

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
7

Mechanisms of Multidrug Resistance in Cancer Chemotherapy.
Karol Bukowski, Mateusz Kciuk, Renata Kontek. Int J Mol Sci 2020
216
7

EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
Tsukasa Shibue, Robert A Weinberg. Nat Rev Clin Oncol 2017
7

Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.
K M Sakamoto, K B Kim, A Kumagai, F Mercurio, C M Crews, R J Deshaies. Proc Natl Acad Sci U S A 2001
774
5

The Different Mechanisms of Cancer Drug Resistance: A Brief Review.
Behzad Mansoori, Ali Mohammadi, Sadaf Davudian, Solmaz Shirjang, Behzad Baradaran. Adv Pharm Bull 2017
479
5

VEGF in Signaling and Disease: Beyond Discovery and Development.
Rajendra S Apte, Daniel S Chen, Napoleone Ferrara. Cell 2019
608
5

NRF2 and the Hallmarks of Cancer.
Montserrat Rojo de la Vega, Eli Chapman, Donna D Zhang. Cancer Cell 2018
551
5

The Complex Interplay between Antioxidants and ROS in Cancer.
Isaac S Harris, Gina M DeNicola. Trends Cell Biol 2020
122
5

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang,[...]. Nat Med 2015
977
5

Epidermal growth factor receptor mutations in lung cancer.
Sreenath V Sharma, Daphne W Bell, Jeffrey Settleman, Daniel A Haber. Nat Rev Cancer 2007
5

Cancer nanomedicine: progress, challenges and opportunities.
Jinjun Shi, Philip W Kantoff, Richard Wooster, Omid C Farokhzad. Nat Rev Cancer 2017
5

Drug resistance in cancer: an overview.
Genevieve Housman, Shannon Byler, Sarah Heerboth, Karolina Lapinska, Mckenna Longacre, Nicole Snyder, Sibaji Sarkar. Cancers (Basel) 2014
5

The entry of nanoparticles into solid tumours.
Shrey Sindhwani, Abdullah Muhammad Syed, Jessica Ngai, Benjamin R Kingston, Laura Maiorino, Jeremy Rothschild, Presley MacMillan, Yuwei Zhang, Netra Unni Rajesh, Tran Hoang,[...]. Nat Mater 2020
458
5

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
Geoffrey R Oxnard, Yuebi Hu, Kathryn F Mileham, Hatim Husain, Daniel B Costa, Philip Tracy, Nora Feeney, Lynette M Sholl, Suzanne E Dahlberg, Amanda J Redig,[...]. JAMA Oncol 2018
346
5



Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Dunyaporn Trachootham, Jerome Alexandre, Peng Huang. Nat Rev Drug Discov 2009
5

Polytherapy and Targeted Cancer Drug Resistance.
Nilanjana Chatterjee, Trever G Bivona. Trends Cancer 2019
77
5

Drug resistance and combating drug resistance in cancer.
Xuan Wang, Haiyun Zhang, Xiaozhuo Chen. Cancer Drug Resist 2019
143
5

Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
Jiantao Hu, Biao Hu, Mingliang Wang, Fuming Xu, Bukeyan Miao, Chao-Yie Yang, Mi Wang, Zhaomin Liu, Daniel F Hayes, Krishnapriya Chinnaswamy,[...]. J Med Chem 2019
97
3

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
Kanak Raina, Jing Lu, Yimin Qian, Martha Altieri, Deborah Gordon, Ann Marie K Rossi, Jing Wang, Xin Chen, Hanqing Dong, Kam Siu,[...]. Proc Natl Acad Sci U S A 2016
395
3

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
María Del Mar Noblejas-López, Cristina Nieto-Jimenez, Miguel Burgos, Mónica Gómez-Juárez, Juan Carlos Montero, Azucena Esparís-Ogando, Atanasio Pandiella, Eva M Galán-Moya, Alberto Ocaña. J Exp Clin Cancer Res 2019
31
6


PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
Mariell Pettersson, Craig M Crews. Drug Discov Today Technol 2019
239
3

Antibody-drug conjugates for cancer.
Cindy H Chau, Patricia S Steeg, William D Figg. Lancet 2019
192
3


Targeting Cancer Stemness in the Clinic: From Hype to Hope.
Caner Saygin, Daniela Matei, Ravindra Majeti, Ofer Reizes, Justin D Lathia. Cell Stem Cell 2019
220
3

Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective.
Jiyou Han, Miae Won, Ji Hyeon Kim, Eugeine Jung, Kyungim Min, Paramesh Jangili, Jong Seung Kim. Chem Soc Rev 2020
36
5

Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer.
Hebao Yuan, Hongwei Guo, Xin Luan, Miao He, Feng Li, Joseph Burnett, Nathan Truchan, Duxin Sun. Mol Pharm 2020
15
13

Cyclooxygenase-2 in cancer: A review.
Nasser Hashemi Goradel, Masoud Najafi, Eniseh Salehi, Bagher Farhood, Keywan Mortezaee. J Cell Physiol 2019
242
3

Designer Peptide and Protein Dendrimers: A Cross-Sectional Analysis.
Rachit Sapra, Ram P Verma, Govind P Maurya, Sameer Dhawan, Jisha Babu, V Haridas. Chem Rev 2019
40
5

The hallmarks of cancer.
D Hanahan, R A Weinberg. Cell 2000
3

Cleavable linkers in antibody-drug conjugates.
Jonathan D Bargh, Albert Isidro-Llobet, Jeremy S Parker, David R Spring. Chem Soc Rev 2019
134
3

Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs.
Michael J Bond, Ling Chu, Dhanusha A Nalawansha, Ke Li, Craig M Crews. ACS Cent Sci 2020
92
3

The quaternary assembly of KRas4B with Raf-1 at the membrane.
Hyunbum Jang, Mingzhen Zhang, Ruth Nussinov. Comput Struct Biotechnol J 2020
25
8

Structural basis for the autoinhibition of c-Abl tyrosine kinase.
Bhushan Nagar, Oliver Hantschel, Matthew A Young, Klaus Scheffzek, Darren Veach, William Bornmann, Bayard Clarkson, Giulio Superti-Furga, John Kuriyan. Cell 2003
606
3

Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery.
Shaoyong Lu, Yuran Qiu, Duan Ni, Xinheng He, Jun Pu, Jian Zhang. Drug Discov Today 2020
36
5

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
713
3

Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.
Shaoyong Lu, Hyunbum Jang, Shuo Gu, Jian Zhang, Ruth Nussinov. Chem Soc Rev 2016
109
3

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R Baer, Joshua A Ballard,[...]. Cancer Discov 2020
432
3


Inflammation and Cancer: Triggers, Mechanisms, and Consequences.
Florian R Greten, Sergei I Grivennikov. Immunity 2019
726
3

The challenge of drug resistance in cancer treatment: a current overview.
Michail Nikolaou, Athanasia Pavlopoulou, Alexandros G Georgakilas, Efthymios Kyrodimos. Clin Exp Metastasis 2018
184
3

Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.
Bing Liu, Liyan Qu, Shigui Yan. Cancer Cell Int 2015
183
3

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Ugur Sahin, Petra Oehm, Evelyna Derhovanessian, Robert A Jabulowsky, Mathias Vormehr, Maike Gold, Daniel Maurus, Doreen Schwarck-Kokarakis, Andreas N Kuhn, Tana Omokoko,[...]. Nature 2020
183
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.